SAN JUAN CAPISTRANO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it expects to issue its second quarter 2025 financial results on Thursday, July 24, 2025.
Conference Call
Ensign invites current and prospective investors to tune into a live webcast to be held the following day, Friday, July 25, 2025, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time), during which Ensign's management will discuss Ensign's second quarter 2025 performance.
To listen to the webcast, or to view any financial or other statistical information required by SEC Regulation G, please visit the Investors section of the Ensign website at http://investor.ensigngroup.net. The webcast will be recorded and will be available for replay via the website until 5:00 p.m. Pacific time on Friday, August 29, 2025.
About Ensign™
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 348 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.
Contact Information
The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it..

| Last Trade: | US$174.14 |
| Daily Change: | -1.25 -0.71 |
| Daily Volume: | 216,763 |
| Market Cap: | US$10.090B |
December 02, 2025 December 02, 2025 December 02, 2025 November 03, 2025 November 03, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load